We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Study Shows Curcumin Kills Childhood Neuroblastoma Cells

By LabMedica International staff writers
Posted on 08 Aug 2017
Treatment-resistant human childhood neuroblastoma tumor cells growing in culture were targeted and destroyed by the natural anti-cancer agent curcumin, which had been delivered to the cells via a novel class of cerium oxide nanoparticles.

Neuroblastomas are cancers that start in early nerve cells and commonly form in the tissue of the adrenal glands, near the kidneys with most cases appearing in children younger than five years old. More...
High-risk neuroblastoma is difficult to treat and frequently develops resistance to standard therapies or recurs.

Investigators at the University of Central Florida (Orlando, USA) synthesized various formulations of nanoceria (cerium oxide nanoparticles) and dextran-coated nanoceria loaded with curcumin. Curcumin is known to have substantial anti-cancer properties, but its low solubility and poor stability have reduced its usefulness in medicinal applications.

In the current study, the anti-cancer activities of the nanoparticle formulations were explored in neuroblastoma models of both MYCN (N-myc proto-oncogene protein)-amplified and non-amplified cell lines. Amplification and overexpression of N-Myc can lead to tumorigenesis. Excess N-Myc is associated with a variety of tumors, most notably neuroblastomas where patients with amplification of the N-Myc gene tend to have poor outcomes.
Results published in the June 9, 2017, online edition of the journal Nanoscale revealed that ceria nanoparticles, coated with dextran and loaded with curcumin, induced substantial cell death in neuroblastoma cells while producing no or only minor toxicity in healthy cells. This formulation evoked prolonged oxidative stress and induced caspase-dependent apoptosis. Overall, nano-therapeutic treatments showed a more pronounced effect in MYCN-amplified cells, which are traditionally more resistant to drug therapies.

"This shows that nanoparticles can be an effective delivery vehicle for cancer drugs," said senior author Dr. Sudipta Seal, professor of materials science at the University of Central Florida. "More research is needed, but we are hopeful it could lead to more effective treatment of this devastating disease in the future."

Related Links:
University of Central Florida


New
Gold Member
Automated Clinical Chemistry Analyzer
Envoy 500+
POC Helicobacter Pylori Test Kit
Hepy Urease Test
New
POC Immunoassay Analyzer
Procise DX
New
Benchtop Thermomixer
Biometra TS1 ThermoShaker
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Immunology

view channel
Image: Accurate immunotherapy selection for esophageal and GEJ carcinomas depends on consistent PD-L1 assessment (credit: Adobe Stock)

FDA Approval Expands Use of PD-L1 Companion Diagnostic in Esophageal and GEJ Carcinomas

Esophageal and gastroesophageal junction carcinomas (GEJ) have a poor prognosis, with approximately 16,250 deaths in the United States in 2025 and a five-year relative survival of 21.9%.... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.